The 3rd LNP Formulation & Process Development Summit
Let’s Talk. See you in Boston!
We are attending the 3rd LNP Formulation & Process Development Summit
The LNP landscape continues to experience remarkable growth and gather momentum throughout 2023, driven by innovative research that is rapidly advancing pipelines, solidifying its position as a safe and significantly adaptable drug delivery solution.
The 3rd LNP Formulation & Process Development Summit remains the superior platform for gaining a comprehensive understanding of LNP development, spanning the initial stages of discovery to sophisticated manufacturing of commercialized drugs.
With a renewed commitment to offering a stage for groundbreaking scientific insights and pioneering approaches that maximize the potential of LNPs, this event delves deeper into the potential of delivering LNPs across oncology as well as variance in payloads, including CRISPR Cas 9, encompassing the versatility of the delivery vehicle.
Stop by the Areterna Booth to learn how Areterna, a Synthgene company, is fueling the next generation of raw materials and services to enable mRNA and oligo therapeutics.
Join us for an exciting presentation by May Guo, Chief Commercial Officer of Areterna, who will discuss cap analogs and NTPs.
Presentation Title:
Democratizing mRNA Therapeutics with Novel Cap Analogs & Modified NTPs
-
Showcasing novel cap analogs and their discovery
-
Unravelling novel modified NTPs
-
Leveraging mRNA capping assays and paired capped/upcapped mRNA standards
Date: Conference Day 2. Tuesday, April 30, 2024
Time: 11:45 AM EST
Speaker: May Guo, Chief Commercial Officer, Areterna LLC
Raw Materials and Services to Enable mRNA and Oligo Therapeutics
Whether your focus is on manufacturing mRNA or pioneering groundbreaking mRNA therapeutics, we are here to support you. Our products are designed to elevate your research to new heights.
Upcoming Events
Catch us at TIDES USA Boston happening from May 14-17, 2024. This event is the industry’s largest & most renowned event to accelerate your oligonucleotides and peptide therapeutics to market.